Samik Pharmaceutical Company LTD. (KOSDAQ:014950)
South Korea flag South Korea · Delayed Price · Currency is KRW
16,350
-1,530 (-8.56%)
At close: Dec 5, 2025

KOSDAQ:014950 Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023
Period Ending
Dec '24 Dec '23
Operating Revenue
55,85751,229
Other Revenue
-0-
55,85751,229
Revenue Growth (YoY)
9.04%-
Cost of Revenue
17,11917,359
Gross Profit
38,73833,870
Selling, General & Admin
32,61228,847
Research & Development
1,9431,757
Amortization of Goodwill & Intangibles
2556.12
Other Operating Expenses
302.34287.89
Operating Expenses
35,06031,073
Operating Income
3,6782,796
Interest Expense
-12.26-18.53
Interest & Investment Income
186.69198.16
Currency Exchange Gain (Loss)
1.751.36
Other Non Operating Income (Expenses)
213.21147.23
EBT Excluding Unusual Items
4,0673,124
Gain (Loss) on Sale of Investments
300.14298.32
Gain (Loss) on Sale of Assets
9.50.07
Asset Writedown
-23.8-
Pretax Income
4,3533,423
Income Tax Expense
830.99453.53
Net Income
3,5222,969
Net Income to Common
3,5222,969
Net Income Growth
18.62%-
Shares Outstanding (Basic)
77
Shares Outstanding (Diluted)
77
Shares Change (YoY)
0.15%-
EPS (Basic)
501.00423.00
EPS (Diluted)
501.00423.00
EPS Growth
18.44%-
Free Cash Flow
3,543874.05
Free Cash Flow Per Share
503.91124.52
Gross Margin
69.35%66.11%
Operating Margin
6.59%5.46%
Profit Margin
6.31%5.80%
Free Cash Flow Margin
6.34%1.71%
EBITDA
5,0294,074
EBITDA Margin
9.00%7.95%
D&A For EBITDA
1,3511,278
EBIT
3,6782,796
EBIT Margin
6.59%5.46%
Effective Tax Rate
19.09%13.25%
Advertising Expenses
565.36753.43
Source: S&P Global Market Intelligence. Standard template. Financial Sources.